Celsius Therapeutics develops precision medicines utilizing genomic and proteomic data to create targeted therapies for patients with cancer and autoimmune diseases. By focusing on the underlying biological mechanisms of these conditions, the company aims to improve treatment efficacy and patient outcomes.
Funding
$15B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing targeted therapies for complex diseases like cancer and autoimmune disorders is challenging due to the heterogeneity of patient populations and the intricate biological mechanisms involved. Traditional drug development approaches often lack the precision needed to effectively address the underlying causes of these conditions, leading to limited efficacy and suboptimal patient outcomes.
Solution
Celsius Therapeutics, now a part of AbbVie, aimed to create precision medicines for cancer and autoimmune diseases by leveraging genomic and proteomic data. The company focused on identifying the specific biological drivers of disease in individual patients, enabling the development of targeted therapies that address the root causes of their conditions. By understanding the unique molecular profiles of patients, Celsius sought to improve treatment efficacy and ultimately enhance patient outcomes.
Target Audience
The target audience included patients with cancer and autoimmune diseases, as well as healthcare providers seeking more effective and personalized treatment options.
Features
- Utilized genomic data to identify novel drug targets
- Leveraged proteomic data to understand disease mechanisms
- Focused on precision medicine approaches for targeted therapies
- Developed therapies for cancer and autoimmune diseases